Literature DB >> 9040055

Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction.

A Matsumori1, Y Furukawa, T Hashimoto, A Yoshida, K Ono, T Shioi, M Okada, A Iwasaki, R Nishio, K Matsushima, S Sasayama.   

Abstract

Cardiac inflammatory responses appear to play a pivotal role in scar formation after acute myocardial infarction. Monocyte chemotactic and activating factor (MCAF) monocyte chemoattractant protein-1 (MCP-1) is a cytokine with chemotactic activity for mononuclear phagocytes, but also for NK cells, T cells, mast cells, and basophils. To investigate the possible involvement of MCAF/MCP-1 in the pathogenesis, its course was studied in patients with acute myocardial infarction. Twenty-three consecutive patients with acute myocardial infarction and 18 patients with angina pectoris were studied. Cytokines were measured by enzyme-linked immunosorbent assay. Plasma levels of interleukin IL-1alpha, IL-1beta, and IL-2 were below the detection limit of our method. IL-6 and interferon-gamma were detected in 17.4%, and tumor necrosis factor-alpha in 13.0% of patients with acute myocardial infarction, but the frequency was not statistically significantly different from that in angina pectoris. The plasma level of MCAF/MCP-1 in myocardial infarction tended to increase at 3 h after the onset of chest pain (133 +/- 19 pg/ml, P= 0.06) and was significantly elevated at 9 h (143 +/- 20 pg/ml) when compared with that in angina pectoris (87 +/- 6 pg/ml, P<0.05). The MCAF/MCP-1 level remained increased during the 24-hours observation period (P<0.01), and maximum level (168 +/- 13 pg/ml) was seen at 24 hour. The level of MCAF/ MCP-1 correlated significantly with the plasma level of another chemokine, IL-8, at 12 h after the onset of chest pain (r=0.51, P<0.05), suggesting that common stimuli mediate the release of both cytokines in myocardial infarction. The identification of MCAF/MCP-1 as an inflammatory mediator in acute myocardial infarction suggests that mononuclear phagocytes may play an important role in the early stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040055     DOI: 10.1006/jmcc.1996.0285

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  18 in total

1.  Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury.

Authors:  Keiichi Hishikari; Jun-ichi Suzuki; Masahito Ogawa; Kazuya Isobe; Teisuke Takahashi; Michihito Onishi; Kiyoshi Takayama; Mitsuaki Isobe
Journal:  Cardiovasc Res       Date:  2008-09-18       Impact factor: 10.787

Review 2.  The role of inflammatory mediators in the failing heart: immunomodulation of cytokines in experimental models of heart failure.

Authors:  A Matsumori; S Sasayama
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

3.  Association of circulating levels of RANTES and -403G/A promoter polymorphism to acute heart failure after STEMI and to cardiogenic shock.

Authors:  Jolana Lipkova; Jiri Parenica; Kamil Duris; Katerina Helanova; Josef Tomandl; Lenka Kubkova; Anna Vasku; Monika Goldbergova Pavkova
Journal:  Clin Exp Med       Date:  2014-06-17       Impact factor: 3.984

4.  Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis.

Authors:  K Fuse; M Kodama; H Hanawa; Y Okura; M Ito; T Shiono; S Maruyama; S Hirono; K Kato; K Watanabe; Y Aizawa
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

5.  Systemic response of peripheral blood leukocytes and their phagocytic activity during acute myocardial infarction.

Authors:  P M Djurdjevic; N N Arsenijevic; D D Baskic; A L Djukic; S Popovic; G Samardzic
Journal:  Exp Clin Cardiol       Date:  2001

Review 6.  Statins and inflammatory markers.

Authors:  Christopher C Case; Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

7.  Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study.

Authors:  Eva C Knudsen; Ingebjørg Seljeflot; Abdelnoor Michael; Jan Eritsland; Arild Mangschau; Carl Müller; Harald Arnesen; Geir Ø Andersen
Journal:  Cardiovasc Diabetol       Date:  2010-09-02       Impact factor: 9.951

Review 8.  Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes.

Authors:  Carlos Gonzalez-Quesada; Nikolaos G Frangogiannis
Journal:  Curr Atheroscler Rep       Date:  2009-03       Impact factor: 5.113

9.  Serum monocyte chemoattractant protein-1 in patients with postoperative infectious complications from gastrointestinal surgery for cancer.

Authors:  Hitoshi Tonouchi; Chikao Miki; Yukinari Ohmori; Minako Kobayashi; Yasuhiko Mohri; Kouji Tanaka; Naomi Konishi; Masato Kusunoki
Journal:  World J Surg       Date:  2004-01-08       Impact factor: 3.352

10.  Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study.

Authors:  Mariana Murea; Thomas C Register; Jasmin Divers; Donald W Bowden; J Jeffrey Carr; Caresse R Hightower; Jianzhao Xu; S Carrie Smith; Keith A Hruska; Carl D Langefeld; Barry I Freedman
Journal:  BMC Nephrol       Date:  2012-11-14       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.